Intravenous Immunoglobulin for the Treatment of Kawasaki Disease | Pediatric Annals
Figure 3 from Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association | Semantic Scholar
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a
Recommended clinical guideline for the management of Kawasaki disease... | Download Scientific Diagram
Clinical Practice Guidelines : Kawasaki disease
AHA's 2004 Guideline On Kawasaki Disease With An Additional 2016 Resource - Tom Wade MD
Kawasaki diseases
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease | Circulation
2017 AHA Guidelines On Kawasaki Disease - A Link And Excerpts - Tom Wade MD
Diagnosis and Management of Kawasaki Disease - American Family Physician
Refractory Kawasaki disease: diagnostic and management challenges | PHMT
2017 AHA Guidelines On Kawasaki Disease - A Link And Excerpts - Tom Wade MD
It is important to be aware that... - Kawasaki Disease Canada | Facebook
Primary care approach to Kawasaki disease | SMJ
Atypical Kawasaki Disease in 2-Months Old Infant Presenting with Aseptic Meningitis | Semantic Scholar
Kawasaki disease: AHA statement and recommendations
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the Ame
Kawasaki Disease and Clinical Outcome Disparities Among Black Children - The Journal of Pediatrics
Kawasaki disease: AHA statement and recommendations
Kawasaki disease in 2019—past controversies, present insights and future directions - Grignani - Pediatric Medicine
Kawasaki Disease (Mucocutaneous Lymph Node Syndrome)
Kawasaki Disease: A Clinical Review
Intravenous Immunoglobulin for the Treatment of Kawasaki Disease | Pediatric Annals
Kawasaki disease: AHA statement and recommendations
